Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications

Ther Deliv. 2019 Nov;10(11):737-747. doi: 10.4155/tde-2019-0025. Epub 2019 Nov 13.

Abstract

Pathologic posterior neovascularization of eye is a major cause of irreversible vision loss and limitations of therapeutics to be successfully delivered to back of the eye has been a main obstacle for its effective treatment. Current pharmacological treatment using anti-VEGF agents being delivered intravitreally are effective but complicated due to anatomical and physiological barriers, as well as administration of high and frequent doses. With expanding horizons of nanotechnology, it can be possible to formulate promising nanoscale delivery system to improve penetration and sustained the release of therapeutic in posterior segment of the eye. Taking into consideration advances in the field of nanoscale delivery systems, this special report focuses on emerging strategies and their applications for treatment of posterior ocular neovascularization.

Keywords: age-related macular degeneration; anti-VEGF; nanotechnology; posterior segment; retinal neovascularization; sustained release.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Administration, Ophthalmic
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / pharmacokinetics
  • Animals
  • Blindness / etiology
  • Blindness / prevention & control
  • Blood-Aqueous Barrier / metabolism
  • Blood-Retinal Barrier / metabolism
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Drug Carriers / chemistry*
  • Genetic Therapy / methods
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Humans
  • Laser Therapy / methods
  • Nanoparticles / chemistry*
  • Ocular Absorption
  • Permeability
  • Photochemotherapy
  • Retina / metabolism
  • Retinal Neovascularization / complications
  • Retinal Neovascularization / therapy*
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / genetics
  • Vision, Low / etiology
  • Vision, Low / prevention & control
  • Vitrectomy

Substances

  • Angiogenesis Inhibitors
  • Drug Carriers
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A